Search results (1)
« Back to NewsCost too high, benefit too small. No new drugs on the NHS
23 June 2025
The NHS will not be offering patients two new drugs that slow progression of Alzheimer’s Disease following a decision by the regulator, NICE. They have assessed that donanemab and lecanemab provide only a small benefit which does not justify the high cost to the health service.